Evaluation of the effectiveness and safety of topical steroids in young children: Clinical cases

Treatment of atopic dermatitis remains a serious challenge due to the prevalence of the disease, significant impact on the quality of life of patients and their families, as well as the risk of sensitization and triggering the “atopic march” in young children. It is known that the development of the disease is associated with a violation of the epidermal barrier; approximately half of the patients have defects in the production of filaggrin protein; in 30%, dermatosis is associated with allergic diseases, most often with food allergies. The course of atopic dermatitis is chronic, often persistently relapsing, and worsens in childhood. First of all, this is due to the peculiarities of the structure and functioning of the skin of children, which predisposes to disruption of its barrier functions, increased transdermal water loss and increased resorptive properties. The above factors determine the need for a particularly careful selection of drugs for external therapy of atopic dermatitis, which can not only cope with the acute period of the disease, achieve remission and control, but also have a sufficient level of safety and good tolerability. Topical corticosteroids remain one of the most commonly used basic therapy, the use of which is recommended by leading Russian and foreign experts. Most often in clinical practice, drugs with strong anti-inflammatory activity are used, one of which is methylprednisolone aceponate 0.1%, approved for use from 4 months of life. Extensive experience has been accumulated in the use of medicines containing this active substance, confirming its effectiveness and minimal side effects. The article presents our own experience of using methylprednisolone aceponate in the form of Comfoderm K cream (with ceramides as a base) in young children (up to 2 years), the results of which are consistent with the data on the high level of safety and effectiveness of the drug obtained earlier.

1. Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836–845. https://doi.org/10.1111/all.12619.

2. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151–160. https://doi.org/10.1016/S0140-6736(03)12193-9.

3. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, FinkWagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.

4. Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3(2):67–73. http://dx.doi.org/10.4168/aair.2011.3.2.67.

5. Fishbein AB, Mueller K, Kruse L, Boor P, Sheldon S, Zee P, Paller AS. Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study. J Am Acad Dermatol. 2018;78(2):336–341. https://doi.org/10.1016/j.jaad.2017.08.043.

6. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol.1980;92(Suppl.):44–47. https://doi.org/10.2340/00015555924447.

7. Consensus report of the European Task Force on Atopic Dermatitis. Severity of scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186:23–31. https://doi.org/10.1159/000247298.

8. Vakharia PP, Chopra R, Silverberg JI. Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials. Am J Clin Dermatol. 2018;19(1):15–22. https://doi.org/10.1007/s40257-017-0299-4.

9. Kubanov AA, Namazova-Baranova LS, Khaitov RM, Ilina NI, Alekseeva EA, Ambarchian ET et al. Clinical Practice Guidelines. Atopic dermatitis. Russian Journal of Allergy. 2021;18(3):44–92. (In Russ.) https://doi.org/10.36691/RJA1474.

10. Wollenberg A, Schnopp C. Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am. 2010;30:351–368. https://doi.org/10.1016/j.iac.2010.06.005.

11. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. https://doi.org/10.1016/j.jaad.2014.03.023.

12. Kovaleva YuS, Vedler AA, Kozhevnikova PE. The role of ceramides in preserving the epidermal barrier. Klinicheskaya Dermatologiya i Venerologiya. 2019;18(4):513–518. (In Russ.) https://doi.org/10.17116/klinderma201918041513.

13. Böhme M, Söderhäll C, Kull I, Bergström A, van Hage M, Wahlgren CF. Filaggrin mutations increase the risk for persistent dry skin and eczema independent of sensitization. J Allergy Clin Immunol. 2012;129(4):1153–1155. https://doi.org/10.1016/j.jaci.2011.11.032.

14. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280–291. http://doi.org/10.1016/j.jaci.2012.12.668.

15. Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006;118(1):214–219. https://doi.org/10.1016/j.jaci.2006.05.004.

16. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73(2):311–318. https://doi.org/10.1016/j.cyto.2014.11.02.

17. Noval Rivas M, Burton OT, Oettgen HC, Chatila T. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol. 2016;138(3):801–811.e9. https://doi.org/10.1016/j.jaci.2016.02.030.

18. Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of Staphylococcus aureus to skin sites of Th2mediated inflammation in a murine model. J Invest Dermatol. 2001;116(5):658–663. https://doi.org/10.1046/j.0022-202x.2001.01331.x.

19. Kecskes A, Heger-Mahn D, Kuhlmann RK, Lange L. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. J Am Acad Dermatol. 1993;29(4):576–580. https://doi.org/10.1016/0190-9622(93)70224-h.

20. Mooney E, Rademaker M, Dailey R, Daniel BS, Drummond C, Fischer G et al. Adverse effects of topical corticosteroids in pediatric eczema: Australasian consensus statement. Australas J Dermatol. 2015;56(4):241–251. https://doi.org/10.1111/ajd.12313.

21. Hong E, Smith S, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr Dermatol. 2011;28(4):393–396. https://doi.org/10.1111/j.15251470.2011.01445.x.

22. Kravvas G, Gholam K. Use of topical therapies for pediatric psoriasis: A systematic review. Pediatr Dermatol. 2018;35(3):296–302. https://doi.org/10.1111/pde.13422.

23. Contento M., Cline A., Russo M. Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions. Am J Clin Dermatol. 2021;22(6):837–851. https://doi.org/10.1007/s40257-021-00623-6.

24. Hachem M, Gesualdo F, Ricci G, Diociaiuti A, Giraldi L, Ametrano O et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr. 2017;43(1):22. https://doi.org/10.1186/s13052-017-0330-7.

25. Fishbein AB, Mueller K, Lor J, Smith P, Paller AS, Kaat A. Systematic review and meta-analysis comparing topical corticosteroids with vehicle/moisturizer in childhood atopic dermatitis. J Pediatr Nurs. 2019;47:36–43. https://doi.org/10.1016/j.pedn.2019.03.018.

26. Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75. https://doi.org/10.1186/s12887-016-0607-9.

27. Machado S. Effective use of methylprednisolone aceponate 0.1% in a 9-month-old infant with atopic eczema and sleep disturbance. J Eur Acad Dermatol Venereol. 2012;(26):14–15. https://doi.org/10.1111/j.1468-3083.2012.04712.x.

28. Ortonne JP. Skin atrophogenicpotencial of methylprednisolone aceponate (MPA). J Eur Acad Dermatol Venerеol. 1994;(3):13–18. https://doi.org/10.1111/j.1468-3083.1994.tb01058.x.

29. Romanyuk FP. Pediatrician’s view about the treatment of atopic dermatitis with methylprednisolone. Meditsinskiy Sovet. 2019;(17):226–234. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-226-234.

30. Ustinov MV, Chaplygin AV. Micronization and other ways to improvethe efficiency and safety of topical drugs in dermatology. Klinicheskaya Dermatologiya i Venerologiya. 2019;18(4):418–427. (In Russ.) https://doi.org/10.17116/klinderma201918041418.